Onkologie. 2008:2(3):156-162

CHRONIC LYMPHOCYTIC LEUKEMIA

Tomáš Kozák
Oddělení klinické hematologie, Fakultní nemocnice Královské Vinohrady, Praha

Chronic lymphocytic leukemia (CLL) is a clonal disease of B lymphocyte with extremly variable course and prognosis. From biological point of view it is a heterogenneic disorder resulting from the imbalance between proliferation activity of the clone and apoptosis. Clinical staging and indication for the therapy initiation is stable for years, however, prognostic factors assessment is useful during the management and follow up of patients with CLL. New therapeutic approaches were developed during past years. A combination of chemotherapy and immunotherapy represents the most used strategy in the treatment of CLL having influence on major variables in CLL, including quality of life. This success is associated with certain economical burden, therefore the intensive treatment should be guided by an experienced haematooncology center.

Keywords: Key words: leukemia, mutation state, chemotherapy, imunotherapy, remission, minimal residual disease.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kozák T. CHRONIC LYMPHOCYTIC LEUKEMIA. Onkologie. 2008;2(3):156-162.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rozman C, Monserrat E. Chronic lymfocytic leukemia, N Engl J Med 1995; 333: 1052-1057. Go to original source... Go to PubMed...
    2. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with special feature regarding survival. Cancer 2004; 101: 3-27. Go to original source... Go to PubMed...
    3. Plass Ch, Byrd JC, Raval A, et al. Molecular profilig of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol 2007; 139: 744-752. Go to original source... Go to PubMed...
    4. Zupo S, Dono M, Massara R, et al. Expression of CD5 and CD38 by human CD5- B cells; requirement for special stimuli. Eur J Immunol 1994; 24: 1426-1433. Go to original source... Go to PubMed...
    5. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854. Go to original source...
    6. Chiorazzi N. Cell proliferation and death: Forgotten features of chronic lymphocytic leukemia. Best Pract Res Clin Hematology 2007; 20: 399-413. Go to original source... Go to PubMed...
    7. Defoiche J, Debacq Ch, Asquith B., et al. Reduction of B cell turnover in chronic lymphocytic leukaemia. Br J Haematol 2008; Aug 15 Ahead of print. Go to original source... Go to PubMed...
    8. Panayiotidis P, Geneshguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993; 85: 439-445. Go to original source... Go to PubMed...
    9. Pedersen IM, Reed JC. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365-2372. Go to original source... Go to PubMed...
    10. Buhl AM, Jurlander J, Jorgensen FS, et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood 2006; 107: 2904-2911. Go to original source... Go to PubMed...
    11. Lin K, Sherrington PD, Denis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409. Go to original source... Go to PubMed...
    12. Dohner H, Stilgenbauer S, Banner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. Go to original source... Go to PubMed...
    13. Binet JL, Caligaris-Cappio F, Katovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Perspectives on the use of new diagnostic tools in the treatment of chronic lymfocytic leukemia. Blood 2006; 107: 859-861. Go to original source... Go to PubMed...
    14. Oscier D, Fegan C, Hillmen P, et al. Guidelines Working Group of the UK CLL Forum, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004; 125: 294-317. Go to original source... Go to PubMed...
    15. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia.Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15; 111(12): 5446-5456. Go to original source... Go to PubMed...
    16. Pekova S, Markova J, Pajer P, et al. Touch-down reverse transcriptase-PCR detection, of IgV(H) rearrangement and Sybr-Green-based real time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn. 2005; 9(1): 23-34. Go to original source... Go to PubMed...
    17. Eichhorst BF, Busch R, Hopfinger G, et al. German CLL Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891. Go to original source... Go to PubMed...
    18. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4): 975-980. Go to original source... Go to PubMed...
    19. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10; 25(35): 5616-5623. Go to original source... Go to PubMed...
    20. Dreger P, Brand R, Hansz J, et al. Chronic Leukemia Working party of the EBMT. Treatment-related mortality and graft-versus-leukemia aktivity using intensity-reduced conditioning. Leukemia 2003; 17: 841-848. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.